Introduction: Blood loss following total knee arthroplasty can lead to significant morbidity and transfusion requirements elevating healthcare costs. Efforts have been made to use hemostatic agents to minimize blood loss and decrease transfusion rates. Floseal (F) is a thrombin-based hemostatic agent with unknown efficacy in achieving these goals in total knee arthroplasty patients. Materials and Methods: We performed a prospective randomized controlled trial on F in patients undergoing total knee arthroplasty with the primary endpoint of assessing blood loss measured through drain output. Patient demographic information, operative side, diagnosis, intra-operative details, implant choice, hospital course, laboratory values, VAS pain scores, knee range of motion, adverse events, transfusion rates, and deviations from protocol were collected. Results: A total of 196 patients were enrolled, and 97 patients were randomized to receive Floseal leaving 99 in the nonFloseal (NF) group. The average age of enrollment was 71.7 with an average BMI of 29.95. There were no significant differences in drain output at 24 h between the F and NF groups (711 vs. 702 ml, respectively, p=0.823). No differences in starting hemoglobin laboratory values were noted between the groups (F=12.1 vs. NF=11.9, p=0.142); however, differences were noted in hemoglobin values on post-operative day 2 (F=10.6 vs. NF=10.0, p=0.001) and day 3 (F=9.9 vs. NF=9.5, p=0.017), which was no longer statistically significant on day 4 (F=9.6 vs. NF=9.4, p=0.76). No differences were noted in patient demographics, operative side, diagnosis, intra-operative details, implant choice, hospital course, laboratory values, and VAS pain scores, knee range of motion or transfusion rates. Complications occurred infrequently. In the acute post-operative period, there were two cases of cellulitis (F=1, NF=1), two deep venous thromboses (N=1, NF=1), and one paralytic ileus (NF=1) which resolved with conservative measures. At the 6-week follow-up, there was one death (unrelated to
surgery), two suture abscesses with cellulitis (F=1, NF=1), and four patients who needed a manipulation under anesthesia to achieve improved range of motion (F=2, NF=2). There was no significant association between Floseal use and the occurrence of these adverse events.
Conclusions: This study suggests that Floseal has no effect on blood loss measured by drain output when used in total knee arthroplasty. There were also no significant adverse events associated with its use. The use of Floseal is safe; however, its use as a hemostatic agent in total knee arthroplasty remains unclear. Princeton University, Princeton, NJ, USA; 3 Texas A&M University, College Station, TX, USA Introduction: Improving the interfacial strength between implants and articular cartilage can enhance the functional performance of treatments for focal cartilage defects. While various methods have been used to tackle this problem, many approaches are targeted at increasing the number of matrix-producing cells that can migrate to the interface [1] . Such approaches may help to reinforce the boundary between the implant and the host tissue as a function of time, but they do not address the problems associated with an initially unstable interface. We developed the concept of using an implant-bound collagen-binding Microbial Surface Component Recognizing Adhesive Matrix Molecule, Collagen Adhesion protein, CNA, to create an immediate bond with articular cartilage. CNA has been shown to attach to collagen in solution [2] via a proposed "Hug" mechanism, whereby the N1 domain associates with the collagen fiber; collagen is wrapped by the N1-N2 linker and, finally, the N1 and N2 domain anchor into one another via multiple hydrophilic interactions [3] . However, the ability of CNA to bind to collagen in articular cartilage is unclear. The objectives of this study were to explore the ability of free CNA and implant-bound CNA to bind to articular cartilage and to quantify the strength of the implant-cartilage interface as a function of presence and absence of CNA at time zero. Our hypothesis was that CNA would increase the interfacial strength between an implant and articular cartilage immediately after implantation. Methods: Recombinant CNA was produced as previously described [2] , labeled with Texas Red, and incubated with thin strips of fresh full-thickness bovine articular cartilage (n=6). Three samples were fixed, paraffin-embedded, and immunohistochemistry was performed using an antibody to the polyhistidine-tag on the CNA (Alpha Diagnostic, TX, USA). The remaining three samples were examined with fluorescence microscopy where CNA was detected using the fluorescent Texas Red tag. Porous polyvinyl alcohol (PVA) scaffolds were manufactured as previously described [4] . The scaffolds were functionalized using a sequential dipping process which results in active carbonate groups on the scaffold's surface which can covalently bond with any protein with which they are incubated [5] . The scaffolds were functionalized to create the following implants: (1) porous PVA with Texas Red-labeled CNA, (2) porous PVA with bovine serum albumin (BSA), (3) porous PVA, unfunctionalized with open carbonate groups (OC), and (4) untreated porous PVA control (UC). Fifteen samples were manufactured per group. To demonstrate the ability of the implant-bound CNA to attach to collagen, five of the scaffolds from each group were incubated for 3 h with a solution of collagen II isolated from bovine articular cartilage and labeled with FITC (Sigma, MO, USA) at 0.25 mg/mL. Each scaffold was washed with three centrifugation steps at 14,000 rpm for 3 min each, and imaged using fluorescence microscopy. A scaffold that was not incubated with the collagen was also imaged to ensure that there was no auto-fluorescence. Middle-zone cartilage discs were isolated from juvenile bovine knees (10 mm diameter, 2 mm thick) and perforated at the center with a 3-mm diameter biopsy punch. Porous PVA scaffolds as described above (n=10 per group) were press-fit into the hole of the cartilage explant and incubated for 4 h. Samples were subjected to a push-out test using a stainless steel indenter which was advanced at 10 μm/s [6] . The maximum load was recorded and normalized to the surface area of the interface for each sample to compute the maximum stress. Results: CNA attached to the collagen fibers found in fresh cartilage tissue as determined by fluorescence microscopy ( Fig. 1a) and immunohistochemistry (Fig. 1b) . Texas Redlabeled CNA was also detected on the surface of the functionalized scaffolds. Implant-bound CNA could also bind collagen type II as demonstrated by a qualitative detection of the FITC tag on the collagen via fluorescence microscopy. As expected the UC and BSA groups did not bind collagen, but surprisingly, the OC group had a much higher presence of collagen than the BSA and UC group (Fig. 2) . The maximum interface strength was approximately four times higher for the CNA and OC groups than the BSA and UC groups (p<0.005) (Fig. 3 ). There was no significant difference between the pushout strength of the CNA and OC groups or between the BSA and UC groups. Discussion: Our results demonstrate that free-CNA and scaffold-bound CNA can bind to collagen type II. This attachment facilitates an increase in push-out strength relative to untreated controls. Moreover, the methods used to functionalize the scaffold, without addition of CNA (the OC group), enabled an increase in push-out strength. It is possible that the residual active carbonate groups are binding to collagen II (Fig. 2 , OC group) through the same covalent bonding that was used to attach the CNA to the surface of the scaffold. This concept is supported by the fact that the BSA scaffolds, where the carbonate groups are occupied, did not exhibit binding to collagen or an increase in interface strength above controls. In summary, this study suggests that a chemical modification of scaffold surfaces might provide an initial bond with articular cartilage. We are currently exploring methods to further enhance this initial strength, by controlling CNA concentration, and exploring the effect of the carbonate groups and CNA on cell migration over time. Introduction/Background Metal-on-metal (MOM) hip resurfacing is being used with increasing frequency in younger patients, but is associated with specific complications including metal hypersensitivity which may manifest as synovitis, bursitis, or peri-prosthetic osteolysis (1) . MRI is an effective means by which to assess painful hip arthroplasty and is the most accurate means by which to measure osteolysis (2, 3). The purpose of this prospective, observational study was to review patterns of osteolysis and synovial proliferation in symptomatic and asymptomatic individuals following hip resurfacing.
Materials and Methods
Patient cohort: Patients were divided into symptomatic and asymptomatic control groups. Demographic data was collected on patient sex, age, body mass index (BMI), and the length of time since arthroplasty placement. Blood results of chromium (Ch) and cobalt (Co) ion levels were recorded, if available. MR Image Acquisition: All scanning was performed using clinical 1.5 T clinical scanners (GE Healthcare, Waukesha, WI, USA) and a three element shoulder coil (MedRad, Indianola, PA, USA) or eight channel cardiac coil (GE Healthcare, Waukesha, WI, USA). Standard of care 2D FSE scanning was performed in three planes with the parameters: TE, 26-34 ms; TR, 4,033-4,500 ms; ETL, 18; BW, ±100 kHz; FOV, 22 cm; NEX, 4-5; acquisition matrix, 512×352; slice thickness, 4 mm (4). Image Analysis: Images were evaluated for the synovial volume and volume of osteolysis via manual segmentation, neurovascular compression, femoral neck erosion, stem bone resorption, and the presence of a fibrous membrane. Statistical Analysis: A Wilcoxon's rank-sum test was performed to compare synovial volume of the symptomatic and asymptomatic groups. The Spearman's correlation coefficient (r) was calculated between synovitis and blood metal ion load in the symptomatic and asymptomatic patients. Statistical significance was taken at p<0.05. Results Forty-two subjects (23 M, 19 F, 52±10 years old) have been scanned to date, comprising 46 cobalt-chromium MOM hip resurfacings. Thirty-two patients (33 hips) had non-specific pain unexplained by radiographs and 10 patients (13 hips) were asymptomatic controls. The mean interval between arthroplasty placement and MRI was 1.8±1.3 years. The mean subject BMI was 26.1±4.9. Synovial expansion was present in 22 of 33 (67%) symptomatic hips and in 9 of 13 (69%) asymptomatic hips. The mean synovial volume was 11.3±38.9 cm 3 in symptomatic hips and 0.6±1.2 cm 3 in asymptomatic hips. The presence or volume of synovitis did not differ significantly between the symptomatic and asymptomatic groups (p=0.09). Synovitis correlated with blood Co (r=0.6, p=0.008) but not Ch (r=0.4, p=0.06) in the symptomatic patients. No correlation was found for either ions in the asymptomatic patients. Osteolysis was present in 5 of 33 (15%) symptomatic hips, with a mean volume of 2.2± 9.8 cm 3 . Osteolysis was not seen in the asymptomatic hips. In the symptomatic group, five cases had femoral neck erosion, two cases showed neurovascular compression, and six cases demonstrated fibrous membrane formation. In the asymptomatic group, stem bone resorption was seen in one case and fibrous membrane formation was seen in one case. Introduction/Background: Articular cartilage defects are a significant source of pain, have a limited ability to heal, and can lead to the development of osteoarthritis. Clinically, few options exist to effectively treat these defects, in part because of the challenges of recreating a mechanically functioning and well-integrated tissue to fill the defect site. To address these limitations, we have developed a macroporous polyvinyl alcohol (PVA) scaffold, the mechanical properties of which can be controlled, while the morphology allows for chondrocytes to migrate and lay down matrix in the scaffold in vitro. 1, 2 Our objective was to assess the ability of our porous PVA scaffold to integrate with articular cartilage in vivo. We hypothesize that integration would be enhanced with partial digestion of the edges of articular cartilage with collagenase. To test this hypothesis, a bilateral trochlear osteochondral rabbit model was used. Materials and Methods: Porous PVA scaffolds were fabricated as previously described 1 . In brief, gelatin sponges were impregnated with 10% w/v PVA in deionized water, subjected to five freeze-thaw cycles, cored, and microtomed to result in cylindrical implants 5 mm diameter×5 mm thick, and digested in collagenase to remove the gelatin.
1,2 Bilateral osteochondral defects were created in the trochlea of 14 New Zealand White rabbits with a cannulated drill to result in defects 3.5 mm diameter×4 mm deep. Right/left defects were randomized to treatment with either collagenase type II or saline for 15 min. PVA implants were press-fit into the defects, flush to the articular cartilage surface. Animals were not immobilized after surgery. Six rabbits were euthanized at 1 month (eight will be sacrificed at 3 months). Gross examinations were performed; the patella-femoral joint from each animal was removed, placed in 10% formalin, and decalcified. Immunostaining for localization of chondroitin sulfate and type II collagen were carried out on formalin-fixed, paraffin sections using the avidin-biotin-peroxidase techniques. The area of chondroitin sulfate staining, as a percent of total scaffold area, was calculated by two blinded observers (Bioquant Osteo II software). The percentage of histologic staining for chondroitin sulfate was analyzed using a twotailed student t test for the collagenase-treated versus control group (p value≤0.05 significant). Results: PVA scaffolds in both groups had a stable and continuous intact interface with adjacent articular cartilage. There was no evidence of synovitis and no damage to the opposing articulating chondral surface of the patella. Histological analysis demonstrated that the scaffolds were populated with cells; many of which were producing type II collagen and chondroitin sulfate. We did not observe significantly greater staining for chondroitin sulfate for the collagenase group (6.4%) vs. that of the saline-treated group (4.3%; p=0.12). Discussion: Our study has shown that porous PVA scaffolds have the potential to integrate with articular cartilage in vivo; gaps were not seen between the scaffold and adjacent tissue, and cells producing cartilage-specific matrix components (collagen type II) were present in the scaffold. The production of collagen type II at such an early time point is a surprising, but encouraging result [5] [6] [7] . In this study, we did not observe a significant difference in early migration of chondrocytes into the scaffold with collagenase digestion. In contrast, other studies have demonstrated increased migration of chondrocytes 3 and increased adhesive force 4 of chondrocytes to articular cartilage in response to chondroitinase digestion, but the effect of digestion on the integration with a non-degradable scaffold has not previously been explored. Whether or not matrix generation is significantly enhanced with collagenase treatment at longer time points will be investigated in the 3-month group. 8 
